Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Delivered through an adeno-associated virus (AAV) vector, the gene is expressed in the liver to increase blood levels of FVIII, thereby reducing the risk of uncontrolled bleeding
Approved Alternatives Available Through NHS and Private Clinics MHRA-approved options include semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), both recommended by NICE for weight management within specialist services under defined eligibility criteria
What if my vial concentration changes between refills
beta-oxidation and energy production pathway research L-Arginine (20mg) nitric oxide precursor
Mode of Action: Amlodipine inhibits the transmembrane influx of Calcium ions into cardiac and vascular smooth muscle
What's New: August 2026 Update TRIUMPH-2 confirmed (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss and up to 1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 confirmed (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH trials are now complete TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 have all reported positive topline results TRIUMPH-4 confirmed: 28.7% weight loss at 68 weeks in 445 participants topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients with BMI 35 reached 30.3% average weight loss no plateau observed TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic now expected Q1 2027 (shifted from the previously estimated Q4 2026) Efficacy Summary Across All Completed Trials Phase 2: The Foundation (2023) The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
US$ 23.20
US$ 27.03
US$ 22.03
US$ 24.90
US$ 22.78
US$ 27.02
